Dyskinesia

Extended Release Amantadine Effective for Reducing Dyskinesia in Parkinson Disease

Extended Release Amantadine Effective for Reducing Dyskinesia in Parkinson Disease

By

ADS-5102 is a promising treatment option: if taken once daily at night, it achieves highest plasma drug concentrations throughout the day when symptoms are most bothersome.

Amantadine Now Available to Treat Parkinson Disease Dyskinesia

Amantadine Now Available to Treat Parkinson Disease Dyskinesia

By

Adamas announced that Gocovri extended-release capsules are now available for the treatment of dyskinesia in Parkinson's patients.

Compulsive Behavior Disorders Common in Patients With Parkinson Disease With Dyskinesia

Compulsive Behavior Disorders Common in Patients With Parkinson Disease With Dyskinesia

By

Patients with dyskinesia had a significantly higher frequency of impulse control disorders.

FDA Approves Parkinson's Dyskinesia Treatment

FDA Approves Parkinson's Dyskinesia Treatment

By

Gocovri is the first treatment for dyskinesia approved for patients with Parkinson's disease who are receiving levodopa therapy.

Extended-Release Amantadine Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease

Extended-Release Amantadine Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease

By

Patients in the treatment group had improved ON and OFF times and no worsening of motor function.

Parkinson-Related Dyskinesia May Respond to Dextromethorphan, Quinidine Combo

Parkinson-Related Dyskinesia May Respond to Dextromethorphan, Quinidine Combo

By

Dextromethorphan is thought to have an impact on all 3 therapeutic pathways for dyskinesia.

Sign Up for Free e-newsletters



CME Focus